This work was produced by Curry et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Curry N, Davenport R, Thomas H, et al. Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis. Southampton (UK): National Institute for Health and Care Research; 2024 Nov. (Health Technology Assessment, No. 28.76.)
Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.
Show detailsFIGURE 11
- Consent procedure overview - Early high-dose cryoprecipitate to reduce mortality...Consent procedure overview - Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
Your browsing activity is empty.
Activity recording is turned off.
See more...